Chr del(13q)

News alerts, weekly reports and conference planners

Chr del(13q)	Chronic Lymphocytic Leukemia	Chr del(13q)	Chronic Lymphocytic Leukemia	ibrutinib + rituximab + obinutuzumab Sensitive: B - Late Trials ibrutinib + rituximab + obinutuzumab Sensitive : B	ibrutinib + rituximab + obinutuzumab Sensitive: B - Late Trials ibrutinib + rituximab + obinutuzumab Sensitive : B
Chr del(13q)	Multiple Myeloma	Chr del(13q)	Multiple Myeloma	bortezomib Resistant: C3 – Early Trials bortezomib Resistant : C3	bortezomib Resistant: C3 – Early Trials bortezomib Resistant : C3
Chr del(13q)	Chronic Lymphocytic Leukemia	Chr del(13q)	Chronic Lymphocytic Leukemia	BMF-219 Sensitive: D – Preclinical BMF-219 Sensitive : D	BMF-219 Sensitive: D – Preclinical BMF-219 Sensitive : D

Associations